Literature DB >> 27373924

Self-perceived Sleep Quality and Quantity in Adults With Asthma: Findings From the CosteAsma Study.

V Sanz de Burgoa1, J Rejas2, P Ojeda3.   

Abstract

BACKGROUND AND
OBJECTIVE: Nocturnal asthma symptoms are associated with poor sleep quality, excessive daytime sleepiness, and poor daytime functioning. The aim of this study was to describe self-perceived sleep quality and quantity in asthmatic adults in a real-world setting according to different determinants of patient health status.
METHODS: A cross-sectional, observational, seasonal, multiwave survey was designed. Allergists nationwide were asked to consecutively survey adult asthmatics aged 18 to 65 years, evenly distributed by seasons and asthma severity (Global Initiative for Asthma criteria). Sleep quality and quantity were assessed using the self-administered Medical Outcomes Study (MOS) Sleep Scale. The Asthma Control Test was applied to ascertain the degree of asthma symptom control.
RESULTS: A total of 1098 individuals (58.7% females, 41.2 [13.6] years) were analyzed. Asthma severity was associated with poor sleep quality and quantity; patients with more severe disease scored higher on the MOS Sleep Scale (P<.001) and also reported significantly fewer daily average hours of sleep (0.3-0.5 hours, P<.001). Level of symptom control and asthma severity were both associated with poor sleep quality and quantity, with the following mean MOS sleep problem index scores: 25.3 (fully controlled asthma), 26.4 (controlled), 32.6 (partly controlled), and 44.6 (uncontrolled) (P<.001), and 48.4 (severe asthma), 39.0 (moderate), 32.6 (mild), and 26.5 (intermittent) (P<.001). Sex was significantly associated with the summary MOS sleep problem index.
CONCLUSIONS: Sleep quality and quantity was significantly associated with poor health status in asthmatic patients. Guidelines should recommend asking about nocturnal asthma symptoms and encourage clinicians to take a global sleep history. Better control of nocturnal asthma symptoms could lead to improved sleep quality and a decrease in daytime sleep-related symptoms.

Entities:  

Keywords:  Asthma; Disability; MOS sleep scale; Real-world setting; Sleep quality and quantity

Mesh:

Year:  2016        PMID: 27373924     DOI: 10.18176/jiaci.0044

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  5 in total

1.  Associations of sleep duration with patient-reported outcomes and health care use in US adults with asthma.

Authors:  Faith S Luyster; Xiaojun Shi; Lynn M Baniak; Jonna L Morris; Eileen R Chasens
Journal:  Ann Allergy Asthma Immunol       Date:  2020-05-07       Impact factor: 6.347

2.  Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life.

Authors:  Diego Bagnasco; Massimiliano Povero; Lorenzo Pradelli; Luisa Brussino; Giovanni Rolla; Marco Caminati; Francesco Menzella; Enrico Heffler; Giorgio Walter Canonica; Pierluigi Paggiaro; Gianenrico Senna; Manlio Milanese; Carlo Lombardi; Caterina Bucca; Andrea Manfredi; Rikki Frank Canevari; Giovanni Passalacqua
Journal:  World Allergy Organ J       Date:  2021-01-27       Impact factor: 4.084

Review 3.  Type 2 inflammation in asthma and other airway diseases.

Authors:  Jorge Maspero; Yochai Adir; Mona Al-Ahmad; Carlos A Celis-Preciado; Federico D Colodenco; Pedro Giavina-Bianchi; Hani Lababidi; Olivier Ledanois; Bassam Mahoub; Diahn-Warng Perng; Juan C Vazquez; Arzu Yorgancioglu
Journal:  ERJ Open Res       Date:  2022-08-01

4.  Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences.

Authors:  Henrik Svedsater; Helen A Doll; Jake Macey; Gail Miles; Lisa Bradshaw; Magdalena Vanya
Journal:  Adv Ther       Date:  2018-08-13       Impact factor: 3.845

Review 5.  Relationship between the Asthma Control Test (ACT) and other outcomes: a targeted literature review.

Authors:  Bas C P van Dijk; Henrik Svedsater; Andreas Heddini; Linda Nelsen; Janita S Balradj; Cathelijne Alleman
Journal:  BMC Pulm Med       Date:  2020-04-03       Impact factor: 3.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.